In Vivo Confocal Fluorescence Imaging of the Intratumor Distribution of the Photosensitizer Mono-l-Aspartylchlorin-e6  by Mitra, Soumya & Foster, Thomas H.
In Vivo Confocal Fluorescence
Imaging of the Intratumor
Distribution of the Photosensitizer
Mono-L-Aspartylchlorin-e61
Soumya Mitra and Thomas H. Foster
Department of Imaging Sciences, University of Rochester,
Rochester, NY 14642 USA
Abstract
We present an in vivo fluorescence microscopic evaluation of intratumor distribution of the photosensitizer mono-
L-aspartylchlorin-e6 (NPe6) in an intradermal mouse EMT6 tumor model. Although the identification of favorable
photophysical and pharmacological properties has led to the development of new photosensitizers in photody-
namic therapy, their intratumor distribution kinetics have remained relatively understudied. In this study, we used
confocal fluorescence microscopy to follow the transport of NPe6 in vivo after systemic administration through the
tail vein. Labeling of vasculature using fluorophore-conjugated anti-CD31 antibodies allows visualization of the
uptake of NPe6 in tumor and normal vessels and its partitioning kinetics into the adjacent parenchyma for 3 hours
after injection. During the initial 60 minutes after injection, the drug is predominantly confined to the vasculature.
Subsequently, it significantly redistributes throughout the extravascular regions with no discernable difference in
its extravasation rate between tumor and normal tissues. Further, we investigate the sensitizer’s altered intratumor
distribution in response to photodynamic therapy irradiation and observe that treatment-induced changes in vessel
permeability caused enhanced accumulation of NPe6 in the extravascular space. Our findings are of immediate
clinical relevance and demonstrate the importance of an in vivo imaging approach to examine the dynamic process
of intratumor drug distribution.
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Introduction
Tissue response to photodynamic therapy (PDT) is understood to be
a dynamic function of the photosensitizer concentration, the interval
between photosensitizer administration and irradiation, the optical
fluence, irradiance, and the local oxygen level. The complex relation-
ships among these parameters have been studied extensively [1–3],
and a recent modeling study has highlighted the interplay between
intratumor photosensitizer distributions and oxygen concentrations
in determining the microscopic deposition of singlet oxygen (1O2)
dose [4]. Intracellular localization sites and bulk tissue pharmacoki-
netics have been thoroughly examined for most of the PDT sensiti-
zers currently in clinical and preclinical evaluations. Investigation of
intracellular localization is important because it determines potential
subcellular targets for 1O2 and the cell death pathways they initiate
[5]. Tissue pharmacokinetics report the temporal photosensitizer up-
take and clearance in the blood and the bulk tissue, and these mea-
surements have played a vital role in guiding the choice of drug-light
intervals for PDT clinical trials based on criteria such as tumor versus
normal tissue selectivity of the photosensitizer. For example, clinical
trials with meso-tetrahydroxyphenyl chlorin (mTHPC) [6] have been
informed by measurements of its time-dependent biodistribution,
which evaluated the optimal drug-light interval based on maximum
sensitizer selectivity [7].
One of the promising second-generation photosensitizers is mono-
L-aspartylchlorin-e6, also known as NPe6, talaporfin sodium, MACE,
laserphyrin, and LS11. Here, we will use the abbreviation NPe6. Suc-
cessful phase I studies with NPe6 have been reported [8–10], and there
is a large body of clinical experience with the drug in Japan that has
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demonstrated excellent antitumor effects [11]. NPe6-PDT is currently
undergoing phase II trials for glioma and phase III trials for metastatic
colorectal cancer and hepatoma (http://www.lsoncology.com/). The
pharmacokinetics of NPe6 and its effectiveness in inducing tumor de-
struction with different drug-light intervals have been examined in pre-
clinical models [12,13], and these studies have shown that the PDT
efficacy of NPe6 is significantly greater at shorter drug-light intervals
that range from 1 to 6 hours compared to an interval of 24 hours.
In fact, the tumor cures reported at these shorter intervals in animal
studies [12] and in human patients [11] were found to be compa-
rable to those obtained with Photofrin-PDT, a US Food and Drug
Administration–approved treatment. In addition, the skin photosensi-
tivity induced by NPe6 is significantly less than that induced by
Photofrin as reported in preclinical [12] and clinical studies [8]. At
these shorter drug-light intervals, pharmacokinetic measurements have
demonstrated that the drug is predominantly in the plasma bound to
albumin and other serum proteins. This has led to the suggestion that
NPe6 is a vascular targeting photosensitizer whose efficacy is aug-
mented by factors such as its high extinction at 664 nm and a plasma
protein binding that may contribute to minimal skin photosensitiza-
tion [14]. In clinical trials of NPe6-PDT initiated by Light Sciences
Oncology (Bellevue, WA), low-intensity light-emitting diodes are in-
serted interstitially, and photoactivating light is delivered for very long
durations. Although the drug-light interval is specified as 1 hour, low-
irradiance irradiations of 5 to 11 hours are reported [9]. It is likely
that significant redistribution of the sensitizer occurs during these long
irradiation times.
With this as background, we decided to systematically investi-
gate the intratumor distribution of NPe6 during drug-light intervals
up to 3 hours using in vivo fluorescence imaging. The confocal
fluorescence imaging experiments in this study were performed in
intradermal tumors in live mice, which allowed us to monitor the
fluorescence of NPe6 in vessels and its extravasation into tissue
after i.v. administration. Quantitative tissue distributions of NPe6
were obtained in tumors and were compared to those in normal tis-
sue. We observed that during a 3-hour period after administration,
NPe6 in the vessels, as reported by the photosensitizer’s fluorescence,
increases monotonically and that the drug partitions at similar rates
from tumor and normal vessels into the interstitial space. In addi-
tion, we examined the distribution of the sensitizer during irradiation
and found that the PDT-induced changes in tumor vessel perme-
ability to NPe6 caused enhanced partitioning of the drug between
the vessels and the extravascular space. This effect was significant,
and it suggests caution in interpreting results of routine pharmaco-
kinetic studies.
Materials and Methods
Photosensitizer
The sensitizer NPe6 (LS11) was kindly provided by Light Sciences
Oncology in powder form. It was dissolved in saline and was stored
in a −4°C freezer according to the manufacturer’s recommendations.
The stock solution was thawed and equilibrated to room temperature
before administering in animals.
Animals and Tumor Model
We investigated the intratumor distribution of NPe6 in EMT6
tumors grown intradermally in the ears of female BALB/c mice
and in normal ears. Mouse mammary sarcoma EMT6 cells were
cultured in Eagle’s basal medium with 10% fetal bovine serum (com-
plete media) at 37°C. Using a 28-gauge needle, tumors were initiated
by an injection of 2 × 105 EMT6 cells into the intradermal space of
the ear pinna of 4- to 6-week-old mice. Approximately 10 days after
inoculation of cells, the tumors reached a diameter of 3 to 5 mm. To
minimize red fluorescence from a chlorophyll degradation product,
during this period, mice were fed a chlorophyll-free diet prepared ac-
cording to the recipe of Holmes et al. [15].
In Vivo Confocal Imaging
In vivo imaging of NPe6 distribution in the ears of anaesthetized
live mice was performed using a custom-built inverted laser scanning
confocal fluorescence microscope [16]. To image the distribution of
NPe6 with respect to the vasculature, the vessels were rendered fluo-
rescent by intradermal (i.d.) injection of a 30-μl solution of 0.1 μg/μl
Alexa Fluor 647–conjugated anti–mouse CD31 antibodies (clone
MEC13.3; Biolegend, San Diego, CA). Because i.d. injection re-
quires the use of less antibody with no concerns regarding toxicity
and enables labeling of vessels that may not be perfused, we adopted
this method versus systemic administration for staining vasculature.
Anti-CD31 was administered 24 hours before imaging to allow clear-
ing of unbound label. An amount of 10 mg/kg NPe6 was injected i.v.
through the tail vein, and the anesthetized mouse was positioned in a
supine position with the tumor in contact with a coverslip mounted
on the stage of the inverted microscope. Before imaging, hair was
removed from the ear using a commercial depiliating agent (Nair;
Church & Dwight Co., Princeton, NJ). The intratumor distribution
of the sensitizer was imaged during the first 3 hours after i.v. injec-
tion. We used sequential two-color excitation of identical fields of
view (FOVs); NPe6 was excited with 514 nm from an argon ion laser
(Coherent, Santa Clara, CA), and the Alexa Fluor 647 was excited
with a 639-nm diode laser (Power Technology Inc., Alexander,
AR). The NPe6 fluorescence was detected using a combination of
a 525LP long pass filter (Chroma Technology, Rockingham, VT)
and an RG645 long pass filter (Schott, Duryea, PA). The Alexa Fluor
647 emission was detected using a combination of a 647LP long
pass filter (Semrock, Rochester, NY) and an RG665 long pass filter
(Schott). The combination of a 100-μm-diameter pinhole and a
10×, 0.45 NA objective gave an optical section thickness of approx-
imately 6 μm as determined by fluorescence edge response measure-
ments. The images were acquired with a lateral resolution of 1 μm/
pixel. Confocal fluorescence spectra of NPe6 were acquired using a
50-μm–core diameter multimode optical fiber that served as the con-
focal aperture, and the collected emission was dispersed by a grating
onto a thermoelectric-cooled charge coupled device [16].
To visualize the distribution of albumin in normal and tumor tis-
sues, 20 mg/kg of Alexa Fluor 555–labeled bovine serum albumin
(BSA; Invitrogen, Carlsbad, CA) was administered to mice through tail
vein injection. The extravasation of albumin from Alexa Fluor 647–
labeled CD31-positive vessels was imaged up to 3 hours after admin-
istration. Alexa Fluor 555 was excited with the 514 nm line from the
argon ion laser, and the emission was detected using a combination of
525LP (Chroma Technology) and OG550LP (Schott) long pass filters.
PDT Treatment
To study the kinetics of NPe6 redistribution in response to PDT
treatment, tumors were subjected to 662-nm irradiation beginning
1 hour post–NPe6 injection. Irradiation was performed at an irra-
diance of 10 mW/cm2. The treatments were briefly interrupted
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periodically to acquire a series of images of NPe6 intratumor distri-
bution from the same FOV.
Image Analysis
The confocal fluorescence images were analyzed using the image
processing software, ImageJ (http://rsb.info.nih.gov/ij/). ImageJ was
used to read in and overlay the images acquired of the vessels stained
by anti–CD31− Alexa Fluor 647 antibody and those of NPe6 or
Alexa Fluor 555–BSA from identical FOV and to generate a dual-
color image of each optical section. A stack of two-color images at
each time point post–NPe6 and BSA administration was created,
and by color segmenting CD31-positive images and thresholding
over the background, the vessels were identified and the temporal
kinetics of NPe6 and BSA distribution in the intravascular regions
were obtained. This ensured that pixels from the extravascular space
were excluded, and drug fluorescence intensity was measured only
from regions that were bounded by CD31-positive signal. To quantify
the extravasation kinetics of NPe6 in response to irradiation, at least
five regions of interest (ROIs) were chosen in each of the tumor optical
sections analyzed. The ROIs were selected beginning from but not in-
cluding the boundary of a CD31-labeled vessel wall and had dimen-
sions of at least 50 μm (height) × 50 μm (width). A width of 50 μm
ensured that the fluorescence intensity was averaged over multiple cell
layers to avoid any sampling errors introduced by analyzing extravas-
cular regions that were in close proximity to the vessel wall.
Results
We labeled vessels with Alexa Fluor 647 fluorophore–conjugated
anti-CD31 antibodies and visualized the distribution of the photo-
sensitizer, NPe6, relative to the vasculature using in vivo imaging.
Figure 1 shows a fluorescence image of anti-CD31–labeled tumor
vessels at a depth of 100 μm in an EMT6 tumor in vivo. The image
was acquired 24 hours after i.d. injection of fluorophore-conjugated
anti–mouse CD31 antibody in the mouse ear. As illustrated, this an-
tibody labeling technique enabled acquisition of high-quality images
of the vasculature with excellent contrast. High signal-to-background
ratio persisted up to 3 days after antibody injection (data not shown).
Shown in Figure 2, A–H, is a representative panel of images illus-
trating the time course of NPe6 accumulation in the same FOVof an
EMT6 tumor after i.v. administration. The vasculature stained by
Alexa Fluor 647–conjugated anti-CD31 and the NPe6 fluorescence
are illustrated in red and green colors, respectively. During the first
60 minutes after injection, NPe6 is predominantly present in the ves-
sels, and only a small fraction has extravasated. However, during
the period between 60 and 180 minutes, there is a significant re-
distribution of the sensitizer, producing an approximately uniform
fluorescence throughout the extravascular space in this FOV. At
the 150- and 180-minute time points, the regions of fluorescence
signal void correspond to lipid-rich sebaceous glands from which
the water-soluble NPe6 is excluded.
Although in most of the imaged tumors, NPe6 was reasonably well
distributed at 3 hours after injection, in some cases, it remained ex-
tremely nonuniform. The panel of images in Figure 3 shows a seg-
mented two-compartment distribution pattern that is presumably
due to the presence of well and poorly perfused vessels that are sep-
arated by only ∼200 μm. The lower left quadrant of the image ex-
hibits distribution kinetics similar to those observed in the images of
Figure 2, whereas the lower right and upper half have extremely low
levels of NPe6 fluorescence in the vessels and the extravascular re-
gions even at 3 hours after administration. Although this phenome-
non was not reproducible in all the animal tumors imaged, the
observation demonstrates the complex heterogeneity of intratumor
drug distribution even at early drug-light intervals.
To compare the distribution kinetics of NPe6 in tumor versus nor-
mal tissue, we imaged the vascular uptake and extravasation of NPe6
in normal ear tissue using the same methodology and imaging tech-
niques. Figure 4 shows a panel of images illustrating the distribution
of NPe6 in normal ear tissue at 15, 30, 60, and 120 minutes after
administration. Similar to the distribution kinetics in tumors, at early
time points, the majority of the drug is retained in the vessels, but at
longer times, it partitions from the vasculature into the adjacent pa-
renchyma. The pattern of severe spatial heterogeneity in NPe6 dis-
tribution as observed in some of the tumors (Figure 3) was not
observed in any of the normal ears imaged.
The kinetics of NPe6 uptake in normal and tumor vessels and its
distribution in the adjacent extravascular space are summarized in
Figure 5, A and B, respectively. Figure 5A shows the mean NPe6
fluorescence intensity measured in vessels up to 3 hours after admin-
istration. We observe a monotonic increase in sensitizer levels in both
normal and tumor vessels, thus indicating that NPe6 remains in cir-
culation during this period. Interestingly, the accumulation of NPe6
occurs at a slightly but significantly faster rate in tumor versus normal
vessels in the range of time points between 120 and 165 minutes.
Figure 5B demonstrates a representative map of the temporal kinetics
of extravascular NPe6 distribution in tumor as a function of distance
from vessels. This distribution was obtained by superimposing an
ROI (20 μm × 105 μm) on the tumor images of Figure 2 as illus-
trated in Figure 5C for the 180-minute time point. A significant
redistribution of the sensitizer occurs during the initial 3-hour period
Figure 1. In vivo confocal image of Alexa Fluor 647–conjugated
anti-CD31–labeled vessels imaged at a depth of 100 μm in an
EMT6 tumor grown in the ear of a BALB/c mouse. Approximately
30 μl of a 0.1-μg/μl concentration of the conjugated antibody
was injected i.d. 24 hours before imaging. Unbound antibody
cleared efficiently producing high contrast images of the tumor
vasculature. The optical section thickness, the in-plane resolution,
and the FOV in the image are 6 μm, 1 μm/pixel, and 600 μm ×
600 μm, respectively.
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after injection, and consistent with the panel of images illustrated in
Figure 2, the sensitizer fluorescence signal near and remote from the
vessels continues to increase with time during this interval.
Our imaging observations illustrate that NPe6 leaks out of both
normal and tumor vessels into the adjacent parenchyma. If NPe6
is bound to albumin in the vessels as has been suggested [14], it
would imply that both tumor and normal vessels are permeable to
albumin. To test this hypothesis, we imaged the egress of Alexa Fluor
555–conjugated BSA from tumor and normal vessels. Shown in Fig-
ure 6, A and B, are images of Alexa Fluor 555–BSA (green) distribu-
tion in tumor and normal tissues, respectively, with the labeled
CD31-positive vasculature in red, acquired ∼3 hours after i.v. albu-
min injection. The images provide strong evidence that BSA par-
titions from tumor and normal vessels and distributes into the
adjacent interstitial space with spatial distribution patterns that are
similar to those observed with NPe6 extravasation in tumor (Figure 2)
and normal (Figure 4) tissues.
We have observed previously that the fluorescence spectrum of
NPe6 is affected by binding to albumin. This offered the oppor-
tunity to use confocal fluorescence spectroscopy measurements to
Figure 2. Panel of in vivo confocal fluorescence images from the same field of view (FOV) of an EMT6 tumor acquired at different time
points after i.v. administration of 10 mg/kg NPe6. The FOV in all the images is 600 μm × 600 μm, and the optical section thickness is
6 μm. NPe6 fluorescence is in green, and CD31-positive vessels labeled by Alexa Fluor 647–conjugated antibody are in red.
Figure 3. Panel of in vivo confocal fluorescence images from the same field of view (FOV) of an EMT6 tumor acquired at different time
points after i.v. administration of 10 mg/kg NPe6. This representative panel of images highlights the severe heterogeneity of NPe6 dis-
tribution observed in some of the tumors that were imaged. The FOV in all the images is 800 μm × 800 μm, and the optical section
thickness is 6 μm. In (H), the regions of fluorescence signal void correspond to lipid-rich sebaceous glands from which the water-soluble
NPe6 is excluded.
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further validate whether NPe6 is bound to serum proteins in extra-
vascular tissue. Vascular and extravascular ROIs were identified in
images, and in vivo confocal fluorescence spectroscopy [16] was per-
formed to acquire NPe6 emission spectra from those ROI. Figure 7A
shows the confocal fluorescence spectrum of NPe6 (circles) acquired
from an extravascular region in the image shown in Figure 2. The
spectrum has a peak at ∼670 nm and is almost identical to that ob-
tained from a solution of NPe6 bound to BSA (Figure 7A, solid line)
but differs significantly from an emission spectrum of NPe6 in aque-
ous solution in the absence of BSA, which has a blue shifted peak
at ∼650 nm (Figure 7B). Further, we note that the aqueous NPe6
(– BSA) spectrum has a full-width at half-maximum of ∼28 nm,
whereas the spectra from both the tumor tissue and the BSA solution
have a full-width at half-maximum of ∼20 nm. This spectral evidence
therefore supports the postulation that NPe6 is bound to BSA or to
other serum proteins as it distributes in the vessels and in the adja-
cent tissue region.
To determine whether PDT changes the kinetics of NPe6 extra-
vasation, we imaged NPe6 distribution after the delivery of specific
treatment fluences after a 1-hour drug-light interval. The panel of
images in Figure 8 demonstrates that there is a significant increase
in NPe6 fluorescence levels in the interstitial space after the delivery
of 5 J/cm2, and the intensity appears to keep increasing even after
20 J/cm2. Quantification of the sensitizer partitioning from the vessels
in response to PDTwas performed by measuring NPe6 fluorescence in
different ROIs adjacent to CD31-positive–labeled vessels. Figure 9
summarizes the mean enhancement of NPe6 fluorescence levels versus
unirradiated controls as a function of irradiation time corresponding to
the delivery of fluences ranging from 3.5 to 20 J/cm2. The plot in
Figure 9A shows that NPe6 levels increase by approximately two-fold
after the delivery of 3.5 J/cm2 and by approximately five-fold after
a 20-J/cm2 irradiation. Because the drug-light interval in irradiated
Figure 4. Panel of in vivo confocal fluorescence images from the
same field of view (FOV) of a normal ear acquired at different time
points after i.v. administration of 10 mg/kg NPe6. The FOV in all
the images is 600 μm × 600 μm, and the optical section thickness
is 6 μm.
Figure 5. (A) Kinetics of NPe6 accumulation in tumor and normal
vessels as a function of time after i.v. administration. The data
points are an average of at least 12 independent measurements,
and the error bars represent SDs. The data points marked with an
asterisk indicate that the NPe6 levels for the normal and tumor tis-
sues at the corresponding time point were statistically significant
with a P value < .05. (B) Representative map of temporal kinetics
of extravascular NPe6 distribution as a function of distance from
CD31-labeled vessels. (C) The 180 minutes image from Figure 2
with the ROI (shaded in white) superimposed on the region where
the data for the representative map in (B) was obtained. The di-
mensions of the ROI are 20 μm × 105 μm.
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tumors is 1 hour, to make an appropriate comparison between the
rates of NPe6 partitioning from irradiated versus unirradiated vessels,
we analyzed the change in NPe6 fluorescence in extravascular regions
of unirradiated tissue normalized to its levels at 1 hour after injection.
As shown in Figure 9B, the five-fold increase in extravascular NPe6
accumulation observed in ∼35 minutes in irradiated tumors requires
approximately 120 minutes in unirradiated controls. Similar levels of
increase in NPe6 extravasation were also observed in tumor tissue that
was subjected to irradiation after a 3-hour drug-light interval (data not
shown). Thus, the rate of NPe6 leakage from PDT-treated vessels is
significantly faster than that observed from unirradiated vessels. These
results therefore demonstrate that NPe6-PDT increases vascular per-
meability and potentiates the accumulation of extravascular sensitizer
during irradiation.
In the panel of images of NPe6 distribution shown in Figure 8, we
note that there is significant fluctuation of fluorescence levels in sev-
eral intravascular regions in response to irradiation. Shown in
Figure 10A is the mean temporal fluctuation in NPe6 amplitude
measured from selected intravascular regions of the imaged tumor
tissue illustrated in Figure 8. We find that NPe6 levels initially fall
with irradiation due to bleaching; however, after 7.5 J/cm2 fluence,
the drug levels rise appreciably and show a decrease only after deliv-
ery of 20 J/cm2. Similar patterns of fluctuation in intravascular NPe6
fluorescence were observed in other tumors that were imaged during
irradiation after a 1- or 3-hour drug-light interval. This observation
provides support that NPe6 remains in circulation for an extended
period of time and also suggests that PDT irradiation may be induc-
ing changes in blood flow rate as has been reported previously by
other investigators for Photofrin-PDT [17].
Discussion
Intratumor drug distribution is an extremely relevant aspect of
PDT and has important implications for the choice of optimum
drug-light interval. These microscopic-scale measurements can
inform the rate and extent of drug distribution with respect to the
vasculature, which is the source of both photosensitizer and oxygen.
Fluorescence imaging is an ideal method for mapping the microscopic
distribution of photosensitizers, because most of these drugs are
fluorescent. However, with very few exceptions [18,19], their time-
dependent intratumor distribution as a function of distance from a
Figure 6. In vivo confocal image of albumin distribution (green) with respect to CD31-positive vasculature (yellow/red) in (A) an
EMT6 tumor and (B) a normal ear at 3 hours postadministration of Alexa Fluor 555–conjugated BSA. The FOV in both the images is
600 μm × 600 μm.
Figure 7. (A) In vivo confocal fluorescence spectrum acquired
from an extravascular tissue region (circles), and emission spec-
trum from a solution of NPe6 dissolved in water in the presence
of BSA (solid line). Both spectra exhibit a peak at ∼670 nm typi-
cal of NPe6 emission. (B) Emission spectrum obtained from a
solution of NPe6 dissolved in water in the absence of BSA with
peak at ∼650 nm (solid line). The fluorescence spectrum from
the tissue is plotted alongside for comparison.
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blood vessel at the time of irradiation remains significantly under-
studied. Zhou et al. [18] explored the distribution of the sensitizer ver-
teporfin as a function of distance from stained blood vessels in frozen
tissue sections from subcutaneous and orthotopic rat tumors. In a
recent study, we investigated the intratumor distribution of the sen-
sitizer mTHPC with respect to perfused vasculature in optical sec-
tions of freshly excised tumor tissue at various times after systemic
injection using a whole-mount technique [19]. We reported that
mTHPC undergoes a remarkable reversal of its initial distribution
pattern with increasing drug-light intervals. A point of view some-
times expressed in the PDT literature considers drug distribution
in vivo to be either predominantly intravascular or extravascular,
but this limited number of intratumor drug distribution studies have
been instrumental in creating an appreciation that the situation is
more complex, dynamic, and interesting.
Although the whole-mount imaging technique allows spatial map-
ping of microscopic distributions with preservation of minimally per-
turbed tumor architecture, these measurements are vulnerable to
systematic error for early times after i.v. administration when sensi-
tizer redistribution is likely to be relatively rapid. Therefore, for sen-
sitizers that are irradiated at short drug-light intervals, it is especially
important to image their initial distributions in vivo. A particular ad-
vantage of this approach is that, because in vivo imaging is noninva-
sive in nature, the same tumors can be imaged repeatedly during a
period of several hours, providing raw unnormalized data from the
same animal, enabling examination of the temporal kinetics in addi-
tion to the microscopic spatial information. Hamblin et al. [20] were
the first to demonstrate the use of laser scanning fluorescence micros-
copy to follow the transport of a photosensitizer in vivo in an animal
tumor model. Their microscope system used a low numerical aper-
ture objective and a large detector aperture to acquire images in a
nonconfocal mode. The in vivo system that we have used in this
study is a laser scanning confocal fluorescence microscope that offers
the advantage of optical sectioning to obtain three-dimensional visu-
alization of the tissue architecture. Imaging depth in our system is
limited by tissue scattering to ∼130 μm in normal ear and tumor
Figure 8. Panel of in vivo confocal images illustrating the accelerated partitioning of NPe6 from the tumor vasculature into the tissue
after irradiation. The first image is from a FOV in a tumor, acquired at 60 minutes after NPe6 administration. The subsequent images are
from the same FOV obtained at different time points corresponding to the delivery of specific fluences ranging from 5 to 20 J/cm2.
Figure 9. (A) Temporal kinetics of NPe6 extravasation in tumor tis-
sue demonstrating an approximately five-fold increase in NPe6
fluorescence in extravascular regions after treatment of up to
20 J/cm2 that corresponds to a total irradiation period of ∼35 min-
utes at an irradiance of 10 mW/cm2 at 662 nm. The data points are
an average of at least 20 measurements from four independent
experiments, and the error bars represent SDs. (B) A similar fold
increase in the partitioning of NPe6 from unirradiated vessels re-
quires ∼120 minutes.
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tissue in mice, but this depth is sufficient to visualize all the relevant
drug distribution kinetics. To the best of our knowledge, no other
imaging technique offers this ability to examine such a dynamic pro-
cess at this level of spatial and temporal resolution.
As illustrated in the images of Figure 2, in the absence of irradia-
tion at 2 to 3 hours after i.v. administration, NPe6 undergoes signif-
icant redistribution from the vasculature into the tumor tissue and
therefore cannot be considered as a purely vascular targeting drug.
This has important implications for the interpretation of preclinical
studies [21,22] and clinical trials [9] with NPe6 that cite a 1-hour
drug-light interval but use irradiation periods that are in the range
of 2 to 5 hours. Further, we note that the drug levels in both the
tumor and normal vessels increase monotonically during the first
3 hours (Figure 5A), thus indicating that the photosensitizer stays
in circulation during a long period of time.
The approximately five-fold increase in intravascular NPe6 fluo-
rescence after i.v. drug administration is an unexpected and surprising
result. Indeed, previous animal studies have reported that plasma levels
of 14C-labeled NPe6 decreased by approximately five-fold within the
2- to 4-hour period after i.v. injection [12,13]. We note, however, that
a pharmacokinetic study of NPe6 plasma levels measured from cancer
patients showed a slower decrease in drug fluorescence levels during
the same period for a range of i.v. injection concentrations of 0.5 to
3.5 mg/kg [14]. This study reported that the plasma clearance rates
dropped at the highest administered dose of 3.5 mg/kg, suggesting a
saturation of the NPe6 elimination process from the plasma. We used
a clinically relevant i.v. injection concentration of 10 mg/kg NPe6, and
it is possible that the kinetics we observed through our fluorescence
measurements may, therefore, have been influenced by this clearance
saturation effect. Clearly, however, this could not account for the ob-
served increase in fluorescence in the normal and tumor vasculature of
the mouse ear. It is possible that this increase results from one or a
combination of the following: a fraction of NPe6 in the plasma may
initially be in an aggregated form, and with time, it may monomerize,
consequently increasing the measured fluorescence; and/or the intra-
vascular drug concentration kinetics in the peripheral circulation of
the ear may be different from that determined by bulk plasma clear-
ance measurements. The conclusion that high concentrations of NPe6
are present in the circulation for an extended period is also supported
by our observation of a significant increase in intravascular drug fluo-
rescence levels after an initial drop in intensity due to irradiation-
induced photobleaching, as shown in Figure 10.
We observe that at 3 hours postadministration NPe6 is well dis-
tributed in the tumor tissue with fluorescence intensity at a distance
of 75 μm from the vessel wall only approximately two-fold lower
than the peak value at the vessel (Figure 5B). This distribution pat-
tern is in sharp contrast to the severely nonuniform distribution ob-
served with mTHPC at the same time point after injection, where
drug levels at 75 μm from perfused vessels were approximately
five-fold lower than at the vessel [19].
The problem of interstitial drug transport and the heterogeneity of
intratumor drug distribution is a subject that has been extensively
studied in the chemotherapy field. The same challenges are faced
in PDT, where nonuniform photosensitizer delivery in tumors may
contribute to the incomplete eradication of tumors after irradiation.
In the images illustrated in Figure 3, we demonstrate the severity of
the nonuniform drug distribution created within a relatively small
area of 800 μm × 800 μm. Although such severe heterogeneity in
NPe6 distribution was not observed in every tumor region that was
imaged, the images reiterate an important point that the successful
distribution of a sensitizer into tumor interstitium is not just governed
by a passive diffusion process and that a feeding vessel’s perfusion sta-
tus and the drug’s binding properties play an important role in its ex-
travasation kinetics. The fact that similarly extreme heterogeneity in
NPe6 distribution was not observed in normal ears may be attributed
to the existence of chaotic vasculature and uneven microcirculation in
tumors [23]. The phenomenon of intermittent tumor vessel perfusion
and its relevance to tumor hypoxia have been recognized in the radi-
ation biology literature for at least two decades [24].
Our observation of NPe6 partitioning into unirradiated tissue dur-
ing time scales that correspond to PDT irradiation periods is further
complicated by the finding that the rate of NPe6 extravasation is ac-
celerated in response to treatment. The panel of images and sum-
marized data in Figures 8 and 9, respectively, clearly indicate that
after a 1-hour drug-light interval, PDT irradiation induces an increase
in vascular permeability to NPe6, which results in enhanced drug
levels in the extravascular tissue. PDT-induced vascular permeability
has been investigated previously by several other investigators, and
an increase in vascular leakiness has been reported post-PDT with
Figure 10. (A) Fluctuation in intravascular NPe6 fluorescence lev-
els as measured in the imaged tumor tissue illustrated in Figure 8.
The tumor was subjected to irradiation 60 minutes after NPe6 ad-
ministration, before which the drug fluorescence levels in the
vessels displayed a monotonic increase. The data points are an
average of six measurements from intravascular ROIs, and the
error bars represent SDs. (B) The first (60 minutes) image from
Figure 8 with a representative intravascular ROI (shaded in white)
indicate where these measurements were made.
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different sensitizers. Fingar et al. [25] performed a detailed study using
intravital microscopy to examine the role of microvascular damage in
PDT and found that Photofrin-PDT resulted in a significant increase
of vascular permeability. Their study reported that increased vascular
leakiness post-PDT, as measured by the leakage of fluorophore-labeled
albumin from the blood vessels into interstitial space, occurred at dis-
crete focal points rather than continuously along the vessel wall. This is
consistent with our observations of NPe6 leakage from discrete regions
of vessels during irradiation (data not shown). Interestingly, in another
study by the same group [26], the authors reported that no significant
change in tumor vascular permeability was observed after NPe6-PDT.
Although the reasons for the discrepancy between their observations
and our current results are not clear, it is possible that the differences
in treatment protocol, such as irradiance, between the two studies
could be attributing. Recent studies have also reported enhanced vas-
cular leakiness in response to PDT irradiation of verteporfin- and
2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH)-sensitized
tumors [27,28]. In fact, Snyder et al. [28] used the HPPH-PDT–
induced vascular permeability to facilitate the improved delivery of
the macromolecular therapeutic agent, Doxil, which resulted in
increased tumor cures. Those authors proposed this combination treat-
ment as a means to exploit increased vascular leakiness caused by
PDT irradiation.
The data presented in this study show that vascular leakiness in-
duced by NPe6-PDT results in increased partitioning of the photo-
sensitizer from the vasculature. This is likely to augment the
deposition of 1O2 dose to tumor cells and potentiate direct tumor
cytotoxicity. This implies that the delivery of a cytotoxic dose in
NPe6-PDT at short drug-light intervals is not limited to the vascu-
lature. Over the long periods of irradiation that are currently being
used in NPe6 clinical trials, this effect would be amplified, and the
PDT damage cannot be solely attributed to a vascular-shutdown phe-
nomenon, as contribution from direct cell injury and/or death will be
nontrivial. Further, as the increase in vascular permeability is ob-
served within short irradiation time scales, it supports the hypothesis
that vessel-permeabilizing effects are initiated by cytoskeletal re-
sponses induced by PDT damage to the endothelium that results
in the rapid formation of large endothelial gaps [27,29].
In conclusion, we have presented an extensive in vivo imaging
study of NPe6 intratumor distribution and showed evidence that
the photosensitizer undergoes significant redistribution from the ves-
sels into interstitial space and that the distribution kinetics are signif-
icantly accelerated when the tumor is subjected to PDT. These
findings are of immediate clinical relevance, as NPe6-PDT is current-
ly undergoing phase II/III clinical trials, and informed treatment
plans based on knowledge of the sensitizer’s distribution is likely to
improve the therapeutic outcome.
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